TW200512016A - Drug-coated stents and methods of use therefor - Google Patents

Drug-coated stents and methods of use therefor

Info

Publication number
TW200512016A
TW200512016A TW092137632A TW92137632A TW200512016A TW 200512016 A TW200512016 A TW 200512016A TW 092137632 A TW092137632 A TW 092137632A TW 92137632 A TW92137632 A TW 92137632A TW 200512016 A TW200512016 A TW 200512016A
Authority
TW
Taiwan
Prior art keywords
drug
methods
coated stents
use therefor
stents
Prior art date
Application number
TW092137632A
Other languages
English (en)
Chinese (zh)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of TW200512016A publication Critical patent/TW200512016A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432Inhibitors, antagonists
    • A61L2300/434Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
TW092137632A 2002-12-31 2003-12-31 Drug-coated stents and methods of use therefor TW200512016A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43733202P 2002-12-31 2002-12-31
US10/749,344 US20050019366A1 (en) 2002-12-31 2003-12-30 Drug-coated stents and methods of use therefor

Publications (1)

Publication Number Publication Date
TW200512016A true TW200512016A (en) 2005-04-01

Family

ID=32717896

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092137632A TW200512016A (en) 2002-12-31 2003-12-31 Drug-coated stents and methods of use therefor

Country Status (11)

Country Link
US (1) US20050019366A1 (enExample)
EP (1) EP1587440A4 (enExample)
JP (1) JP2006512143A (enExample)
KR (1) KR20050091047A (enExample)
AU (1) AU2003300466A1 (enExample)
BR (1) BR0317909A (enExample)
CA (1) CA2512056A1 (enExample)
IL (1) IL169440A0 (enExample)
MX (1) MXPA05006999A (enExample)
TW (1) TW200512016A (enExample)
WO (1) WO2004060318A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US6955876B2 (en) * 2000-11-01 2005-10-18 Kane Michael D Compositions and systems for identifying and comparing expressed genes (mRNAs) in eukaryotic organisms
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP1699527A1 (en) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis
US20060013855A1 (en) * 2004-04-05 2006-01-19 Medivas, Llc Bioactive stents for type II diabetics and methods for use thereof
US8163269B2 (en) * 2004-04-05 2012-04-24 Carpenter Kenneth W Bioactive stents for type II diabetics and methods for use thereof
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20060125144A1 (en) * 2004-12-14 2006-06-15 Jan Weber Stent and stent manufacturing methods
US7335697B2 (en) 2004-12-23 2008-02-26 Depuy Products, Inc. Polymer composition comprising cross-linked polyethylene and methods for making the same
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2007038246A2 (en) * 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
US8343230B2 (en) * 2005-09-22 2013-01-01 Depuy Products, Inc. Orthopaedic bearing material
US20070077268A1 (en) * 2005-09-30 2007-04-05 Depuy Products, Inc. Hydrophobic carrier modified implants for beneficial agent delivery
WO2007067744A2 (en) * 2005-12-07 2007-06-14 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US7812098B2 (en) 2006-03-31 2010-10-12 Depuy Products, Inc. Bearing material of medical implant having reduced wear rate and method for reducing wear rate
EP2019645A4 (en) * 2006-05-02 2013-03-06 Medivas Llc RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
DE602007009345D1 (de) 2006-08-25 2010-11-04 Depuy Products Inc Material zum Tragen eines medizinischen Implantats
DE102006042313A1 (de) * 2006-09-06 2008-03-27 Biotronik Vi Patent Ag Biokorrodierbares metallisches Implantat mit einer Beschichtung oder Kavitätenfüllung aus Gelatine
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
WO2008091925A2 (en) * 2007-01-23 2008-07-31 Cook Incorporated Treatment of aortic dissection or aneurysm
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
CA2731323A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
WO2010019716A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008042603A1 (de) * 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implantat sowie Verfahren zur Herstellung einer degradationshemmenden Schicht auf einer Körperoberfläche eines Implantats
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
JP6045575B2 (ja) 2011-06-23 2016-12-14 ディーエスエム アイピー アセッツ ビー.ブイ. 薬物送達のための新規な生分解性ポリエステルアミドコポリマー
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
CA2969171C (en) 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US10610669B2 (en) 2016-03-16 2020-04-07 Krishna Rocha-Singh, M.D. Apparatus and method for promoting angiogenesis in ischemic tissue
US10065018B2 (en) 2016-03-16 2018-09-04 Krishna Rocha-Singh Apparatus and method for promoting angiogenesis in ischemic tissue

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095415A (en) * 1958-05-30 1963-06-25 Ciba Ltd Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group
CH428043A (fr) * 1965-08-16 1967-01-15 Sandoz Ag Procédé de fabrication de colorants de dispersion isothiazolantroniques
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
JPS63184364A (ja) * 1987-01-27 1988-07-29 Toshiba Corp 半導体装置の製造方法
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JP3266005B2 (ja) * 1995-09-19 2002-03-18 藤沢薬品工業株式会社 エアゾール製剤およびその製造方法
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
CA2282593A1 (en) * 1997-03-31 1998-10-08 Du Pont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US20020188037A1 (en) * 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
US6206835B1 (en) * 1999-03-24 2001-03-27 The B. F. Goodrich Company Remotely interrogated diagnostic implant device with electrically passive sensor
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Jnk억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
IL145757A (en) * 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
ATE449763T1 (de) * 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics

Also Published As

Publication number Publication date
CA2512056A1 (en) 2004-07-22
WO2004060318A2 (en) 2004-07-22
JP2006512143A (ja) 2006-04-13
MXPA05006999A (es) 2005-08-18
AU2003300466A1 (en) 2004-07-29
EP1587440A4 (en) 2006-08-02
IL169440A0 (en) 2007-07-04
BR0317909A (pt) 2005-11-29
KR20050091047A (ko) 2005-09-14
WO2004060318A3 (en) 2004-10-21
US20050019366A1 (en) 2005-01-27
EP1587440A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
TW200512016A (en) Drug-coated stents and methods of use therefor
WO2003009777A3 (en) Delivery of therapeutic capable agents
EP1648339A4 (en) IMPLANTABLE PROSTHESES, PARTICULARLY FOR TRANSARTERIAL APPLICATION FOR THE TREATMENT OF AORTIC STENOSIS AND METHODS FOR IMPLANTATION OF SAID PROSTHESES
WO2004069201A3 (en) Compounds useful in coating stents to prevent and treat stenosis and restenosis
TW200603838A (en) Extended release biodegradable ocular implants
WO2005051229A3 (en) Devices delivering therapeutic agents and methods regarding the same
ATE428372T1 (de) Beschichtung von stents zur verhinderung von restenose
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
GB0223040D0 (en) Therapeutic compounds
MXPA02012410A (es) Metodo para tratar enfermedades cardiovasculares usando rapamicina.
MXPA05011620A (es) Dispositivos medicos y metodos para inhibir la proliferacion de celulas de musculo liso.
WO2004024093A3 (en) Device and method for treating restenosis
DE602007012273D1 (de) Vorrichtung zum in-situ-embolieschutz
DE60233594D1 (de) Gerät zur ablage von gerollten prothesen
EP1355588A4 (en) RELEASE OF THERAPEUTIC CAPACITY AGENTS
ATE469615T1 (de) Künstliches, vaskuläres transplantat sowie verfahren zu seiner herstellung und seinem gebrauch
WO2005092244A3 (en) Stent system for preventing restenosis
TW200500099A (en) Sustained release device and method for ocular delivery of adrenergic agents
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
DE69841041D1 (de) Stent beschichtet mit dna
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis
IL163976A0 (en) Pharmaceutical combination for the treatment of benign prosttic hyperplasia or for the long-term prevention of acute urinary retention
WO2003059192A3 (en) C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
NZ519722A (en) Treatment of diabetic ulcers
WO2004039330A3 (en) Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls